RxDoctor Payments Data

Jacqueline Belizar

Medical · New York, NYNPI 1619351889

Payments from drug & device makers

$962in general payments, 2019–2025

Across 35 payments — averaging $27.49 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Mirati Therapeutics, Inc.$164
  • Eisai Inc.$123
  • Johnson & Johnson$117
  • Novartis$94
  • Daiichi Sankyo Inc.$89
  • Seagen Inc.$85
  • plus $291 from 11 others

What the payments were for

  • Food & beverage$89793%
  • Education$657%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$962 in reported general payments places this provider in the 65th percentile of 2,395 medical providers in New York.

See all medical providers in New York

Medicare billing

Part B allowed, 2024
$5,289
Medicare patients
48
Services billed
177

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
TagrissoOsimertinib Mesylate29$711,654
TafinlarDabrafenib Mesylate12$61,238
CreonLipase/Protease/Amylase13$24,771
Imatinib Mesylate26$9,113
EliquisApixaban15$8,379
Potassium Chloride20$586
Prochlorperazine Maleate25$384
Dexamethasone17$371
Pantoprazole Sodium29$359
Anastrozole19$220
Lidocaine-PrilocaineLidocaine/Prilocaine16$195
Prednisone31$162
Acyclovir14$122
Levothyroxine Sodium11$77

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaTagrisso$28$711,65429 claims
NovartisTafinlar$94$61,23812 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 2,395 medical providers in New York.

Other medical in New York

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →